Kitazato

Kitazato Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Kitazato (368A.T) as of Nov 17, 2026 is 93.08 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 113.32 % — a change of -17.86% (lower).

Cash Conversion

93.08 %

YoY

-17.86%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Kitazato is 2025 93.08 % . Cash Conversion Rate (OCF/Net Income) of Kitazato was 2024 113.32 % . It decreases by -17.86% lower compared to the previous year.

The Kitazato Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2023
63.20 JPY
Jan 1, 2024
113.32 JPY
Jan 1, 2025
93.08 JPY
The Kitazato Cash Conversion history
YEARCash ConversionYoY
93.08 %-17.86%
113.32 %+79.29%
63.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kitazato Stock analysis

What does Kitazato do? Kitazato Corp manufactures and sells medical devices, reagents, and related products for infertility treatment, specializing in reproductive engineering technology for artificial insemination, in vitro fertilization, and cell cryopreservation. The company produces consumables such as medical equipment and reagents used in in vitro fertilization and intracytoplasmic sperm injection, including media, cryo devices, medical devices, and micro tools. Kitazato Corp distributes its products globally, serving markets in Japan, Europe, the United States, China, and India, with a focus on research reagents and medical equipment for infertility treatment. The firm also manufactures and sells medical equipment parts, provides genetic testing services, and offers medical equipment for the elderly. Additionally, Kitazato Corp engages in market research, acquisition of local licenses, and contract management of living cells, expanding its reach into regenerative medicine and related fields. These services and products target healthcare providers, fertility clinics, and research institutions worldwide. Kitazato Corp's revenue streams include the sale of consumables, medical devices, and reagents, as well as genetic testing and contract management services. The company's global distribution network supports sales across key regions, with a strong emphasis on infertility treatment solutions and regenerative medicine technologies. Kitazato is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kitazato stock

Cash Conversion Rate (OCF/Net Income) of Kitazato is 93.08 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Kitazato changed from 113.32 % to 93.08 %, representing a -17.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Kitazato since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Kitazato with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Kitazato

All Key Metrics — Kitazato